NMR conformational analysis of p-tolyl furanopyrimidine 2′-deoxyribonucleoside and crystal structure of its 3′,5′-di- O-acetyl derivative

Bioorganic and Medicinal Chemistry

Volumn 13, Issue 4, 2005, Pages 1231-1238

  Esho, Noor ^a   Desaulniers, Jean Paul ^b   Davies, Brian ^a   Chui, Helen M P ^b   Rao, Meneni Srinivasa ^a   Chow, Christine S ^b   Szafert, Slawomir ^c   Dembinski, Roman ^a  

^a OAKLAND UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF WROC AW   (Poland)

Author keywords

Conformation; Furanopyrimidine; Nucleosides

Indexed keywords

3',5' DI O ACETYL 3 (2' DEOXY BETA DEXTRO RIBOFURANOSYL) 6 (4 METHYLPHENYL) 2,3 DIHYDROFURO[2,3 D]PYRIMIDIN 2 ONE; 4 TOLYLFURANOPYRIMIDINE; ANTIVIRUS AGENT; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONFORMATION; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG SYNTHESIS; PROTON NUCLEAR MAGNETIC RESONANCE;

CRYSTALLOGRAPHY, X-RAY; DEOXYRIBONUCLEOSIDES; MAGNETIC RESONANCE SPECTROSCOPY; PYRIMIDINES; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 12844286981     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.11.013     Document Type: Article

References (62)

1. See for example: G.M. Grotenbreg, M.S.M. Timmer, A.L. Llamas-Saiz, M. Verdoes, G.A. van der Marel, M.J. van Raaij, H.S. Overkleeft, and M. Overhand J. Am. Chem. Soc. 126 2004 3444 3446
2. R.M. van Well, L. Marinelli, C. Altona, K. Erkelens, G. Siegal, M. van Raaij, A.L. Llamas-Saiz, H. Kessler, E. Novellino, A. Lavecchia, J.H. van Boom, and M. Overhand J. Am. Chem. Soc. 125 2003 10822 10829
3. Recent work: V.E. Marquez, T. Ben-Kasus, J.J. Barchi Jr., K.M. Green, M.C. Nicklaus, and R. Agbaria J. Am. Chem. Soc. 126 2004 543 549
4. See for example: Y.F. Shealy, C.A. O'Dell, G. Arnett, and W.M. Shannon J. Med. Chem. 29 1986 79 84
5. R.A. Sharma, I. Kavai, R.G. Hughes Jr., and M. Bobek J. Med. Chem. 27 1984 410 412
6. E. De Clercq, J. Descamps, J. Balzarini, J. Giziewicz, P.J. Barr, and M.J. Robins J. Med. Chem. 26 1983 661 666
7. M.W. Flanagan, and R.W. Wagner The Development of C-5 Propyne Oligonucleotides as Inhibitors of Gene Function C.A. Stein A.M. Krieg Applied Antisense Oligonucleotide Technology 1998 Wiley-Liss New York 174 191
8. N.G. Kundu, J.S. Mahanty, C. Chowdhury, S.K. Dasgupta, B. Das, C.P. Spears, J. Balzarini, and E. De Clercq Eur. J. Med. Chem. 34 1999 389 398
9. M.J. Robins, R.S. Vinayak, and S.G. Wood Tetrahedron Lett. 31 1990 3731 3734
10. K.A. Cruickshank, and D.L. Stockwell Tetrahedron Lett. 29 1988 5221 5224
11. M.J. Robins, and P.J. Barr J. Org. Chem. 48 1983 1854 1862
12. M.J. Robins, and P.J. Barr Tetrahedron Lett. 22 1981 421 424
13. G.T. Crisp, and B.L. Flynn J. Org. Chem. 58 1993 6614 6619
14. Review: V.A. Korshun, E.V. Manasova, and Yu.A. Berlin Bioorg. Khim. 23 1997 324 387 (in Russian)
15. Recently reported cyclizations: E. Coutouli-Argyropoulou, M. Tsitabani, G. Petrantonakis, A. Terzis, and C. Raptopoulou Org. Biomol. Chem. 1 2003 1382 1388
16. A.R. Pike, L.C. Ryder, B.R. Horrocks, W. Clegg, M.R.J. Elsegood, B.A. Connolly, and A. Houlton Chem. Eur. J. 8 2002 2891 2899
17. C.J. Yu, H. Yowanto, Y. Wan, T.J. Meade, Y. Chong, M. Strong, L.H. Donilon, J.F. Kayyem, M. Gozin, and G.F. Blackburn J. Am. Chem. Soc. 122 2000 6767 6768
18. (a) 5-(2-Bromovinyl)uracil undergoes cyclization with t-BuOK: R.C. Bleackley, A.S. Jones, and R.T. Walker Tetrahedron 32 1976 2795 2797
19. 3 (cat.) cyclization: V. Aucagne, F. Amblard, and L.A. Agrofoglio Synlett 2004 2406 2408
20. NIS/NBS halocyclization: M.S. Rao, N. Esho, C. Sergeant, and R. Dembinski J. Org. Chem. 68 2003 6788 6790
21. C. McGuigan, H. Barucki, S. Blewett, A. Carangio, J.T. Erichsen, G. Andrei, R. Snoeck, E. De Clercq, and J. Balzarini J. Med. Chem. 43 2000 4993 4997
22. A. Brancale, C. McGuigan, G. Andrei, R. Snoeck, E. De Clercq, and J. Balzarini Bioorg. Med. Chem. Lett. 10 2000 1215 1217
23. C. McGuigan, C.J. Yarnold, G. Jones, S. Velázquez, H. Barucki, A. Brancale, G. Andrei, R. Snoeck, E. De Clercq, and J. Balzarini J. Med. Chem. 42 1999 4479 4484
24. S. Srinivasan, C. McGuigan, G. Andrei, R. Snoeck, E. De Clercq, and J. Balzarini Nucleosides, Nucleotides, Nucleic Acids 20 2001 763 766
25. O. Bidet, C. McGuigan, G. Andrei, R. Snoeck, E. De Clercq, and J. Balzarini Nucleosides, Nucleotides, Nucleic Acids 22 2003 817 819
26. C. McGuigan, A. Brancale, G. Andrei, R. Snoeck, E. De Clercq, and J. Balzarini Bioorg. Med. Chem. Lett. 13 2003 4511 4513
27. C. McGuigan, A. Carangio, R. Snoeck, G. Andrei, E. De Clercq, and J. Balzarini Nucleosides, Nucleotides, Nucleic Acids 23 2004 1 5
28. C. McGuigan, R.N. Pathirana, R. Snoeck, G. Andrei, E. De Clercq, and J. Balzarini J. Med. Chem. 47 2004 1847 1851
29. Reviews: E.D. De Clercq Med. Res. Rev. 23 2003 253 274
30. J. Balzarini, and C. McGuigan Biochim. Biophys. Acta 1587 2002 287 295
31. J. Balzarini, and C. McGuigan J. Antimicrob. Chemother. 50 2002 5 9
32. C. McGuigan, A. Brancale, H. Barucki, S. Srinivasan, G. Jones, R. Pathirana, A. Carangio, S. Blewett, G. Luoni, O. Bidet, A. Jukes, C. Jarvis, G. Andrei, R. Snoeck, E. De Clercq, and J. Balzarini Antiviral Chem. Chemother. 12 2001 77 89
33. C. McGuigan, A. Brancale, H. Barucki, S. Srinivasan, G. Jones, R. Pathirana, S. Blewett, R. Alvarez, C.J. Yarnold, A. Carangio, S. Velázquez, G. Andrei, R. Snoeck, E. De Clercq, and J. Balzarini Drugs Future 25 2000 1151 1161
34. C. McGuigan, S. Velázquez, E. De Clercq, and J. Balzarini Antiviral Chem. Chemother. 8 1997 519 527
35. C. McGuigan, M.-J. Camarasa, H. Egberink, K. Hartmann, A. Karlsson, C.-F. Perno, and J. Balzarini Int. Antiviral News 5 1997 19 21
36. K. Sonogashira J. Organomet. Chem. 653 2002 46 49
37. K. Sonogashira Cross-coupling Reactions to sp Carbon Atoms F. Sonogashira Diederich P.J. Stang Metal-Catalyzed Cross-Coupling Reactions 1998 Wiley-VCH Weinheim 203 230
38. G. Zeni, and R.C. Larock Chem. Rev. 104 2004 2285 2309
39. R.C. Larock Palladium-Catalyzed Annulation J. Tsuji Perspectives in Organopalladium Chemistry for the XXI Century 1999 Elsevier Lausanne, Switzerland 111 124
40. R.C. Larock Pure Appl. Chem. 71 1999 1435 1442
41. R.C. Larock J. Organomet. Chem. 576 1999 111 124
42. A.V. Kel'in, and V. Gevorgyan J. Org. Chem. 67 2002 95 98
43. P.K. Chang, and A.D. Welch J. Med. Chem. 6 1963 428 430
44. N. Esho, B. Davies, J. Lee, and R. Dembinski Chem. Commun. 2002 332 333
45. C. Altona, and M. Sundaralingam J. Am. Chem. Soc. 94 1972 8205 8212
46. W. Saenger Principles of Nucleic Acids Structure 1984 Springer Verlag New York pp 1-82
47. For definition of angles see: N.C. Seeman, J.M. Rosenberg, F.L. Suddath, J.J. Park Kim, and A. Rich J. Mol. Biol. 104 1976 142 143
48. Numbering of the six-membered ring for furanopyrimidine used in this work differs from the parent pyrimidine (uridine) ring and follows RF 10623: Ring Systems Handbook, American Chemical Society, Chemical Abstracts Service: Columbus, 1993; p 498RSF
49. See for example: D. Neuhaus, and M.P. Williamson The Nuclear Overhauser Effect in Structural and Conformational Analysis 2000 Wiley-VCH New York pp 1-619
50. P.A. Hart, and J.P. Davis J. Am. Chem. Soc. 94 1972 2572 2577
51. H. Rosemeyer, G. Tóth, B. Golankiewicz, Z. Kazimierczuk, W. Bourgeois, U. Kretschmer, H.-P. Muth, and F. Seela J. Org. Chem. 22 1990 5484 5790
52. C. Altona, and M. Sundaralingam J. Am. Chem. Soc. 95 1973 2333 2344
53. 2 (sin 36°+ sin 72°)
54. Numbering used in original reference given in parentheses
55. D. Cremer, and J.A. Pople J. Am. Chem. Soc. 97 1975 1354 1358
56. 13C signals of 88.8 ppm with H-4′ and 88.3 ppm with H-1′ proton
57. 13C NMR.
58. m/z for most intense peak of isotope envelope
59. 3 group
60. Sheldrick, G. M. SHELXL-97. University of Göttingen, Germany, 1997
61. D.T. Cromer, and J.T. Waber J.A. Ibers W.C. Hamilton International Tables for X-ray Crystallography Vol. 4 1974 Kynoch Birmingham, England 72 98 149-150; Tables 2.2B and 2.3.1
62. H.D. Flack Acta Cryst. A39 1983 876 881